Orgenesis Inc. Subsidiary Theracell Secures $1 Million Convertible Loan Agreement with Alpha Prosperity Fund, Offering Up to $10 Million Credit Facility
Orgenesis Inc.'s subsidiary, Theracell Laboratories IKE, has secured a $1 million Convertible Loan Agreement with Alpha Prosperity Fund SPC, featuring a 10% interest rate and a 36-month maturity. The agreement allows for a $10 million credit facility and includes a conversion option for the lender to acquire up to 80% equity in Orgenesis or Theracell, pending shareholder approval. Additionally, a warrant for 15% of the fully diluted share capital is included, exercisable over three years. This move aims to enhance Orgenesis's operational capabilities and growth potential.
Orgenesis Inc., through its subsidiary Theracell Laboratories IKE, has entered into a new Convertible Loan Agreement with Alpha Prosperity Fund SPC, providing Theracell with an initial loan of $1 million. The loan bears a 10% annual interest rate and matures in 36 months, with prepayment allowed within the first 30 days. Additionally, Theracell has secured access to a $10 million credit facility, subject to the Lender’s discretion. A significant feature of the agreement allows the Lender to convert the loan into equity, potentially holding up to 80% of the share capital of Orgenesis or Theracell, pending shareholder approval. The agreement also includes the issuance of a warrant for 15% of the fully diluted share capital of either entity, exercisable over three years. This strategic financial move aims to bolster Orgenesis’s operational capabilities and growth potential. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orgenesis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-013758), on September 16, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
